Advertisement
Screener

TARSUS PHARMACEUTICALS, INC. (TARS) Graph

TARS Revenue Flow

Filed revenue amounts for 2026-04-01 to 2026-06-30. Coverage is partial. Unconnected amounts are separate disclosures; they must not be added together.

  • 2026-06-30: Revenue $173.91M; Cost of revenue $12.11M; Research and development $31.01M; Selling, general and administrative $150.70M.
  • 2026-03-31: Revenue $162.05M; Cost of revenue $9.40M; Research and development $22.35M; Selling, general and administrative $136.43M.
  • 2025-12-31: Revenue $151.67M*; Cost of revenue (m); Research and development $18.04M*; Selling, general and administrative $130.68M*.
  • 2025-09-30: Revenue $118.70M; Cost of revenue (m); Research and development $16.28M; Selling, general and administrative $108.63M.

Product or service

Separate filed amounts; connecting flows are not established. Components and totals may overlap.

TARS revenue flowFiled amounts. Only explicit calculation relationships connect amounts; dimensional membership alone does not establish an additive flow.Product$173.91MLicense AndCollaboration$0.00Revenue$173.91MCost of revenue$12.11MOperating income-$19.91MOther income, net-$281.00KResearch & development$31.01MSelling, general& administrative$150.70MIncome tax$2.72MNet income-$18.55M

Segment

Separate filed amounts; connecting flows are not established. Components and totals may overlap.

TARS revenue flowFiled amounts. Only explicit calculation relationships connect amounts; dimensional membership alone does not establish an additive flow.Reportable Segment$173.91MRevenue$173.91MCost of revenue$12.11MOperating income-$19.91MOther income, net-$281.00KResearch & development$31.01MSelling, general& administrative$150.70MIncome tax$2.72MNet income-$18.55M

Finer product or service dollar figures and nonoverlapping groupings are shown only where supported by the retained filing evidence. Growth percentages are never converted to revenue dollars.

Historical revenue and expense breakdown

Revenue and expense 3 month

Period endRevenueCost of revenueResearch and developmentSelling, general and administrativeOperating expensesIncome taxNet income
2026-06-30$173.91M$12.11M$31.01M$150.70M(m)$2.72M-$18.55M
2026-03-31$162.05M$9.40M$22.35M$136.43M(m)$2.35M-$6.97M
2025-12-31$151.67M*(m)$18.04M*$130.68M*(m)(m)-$7.96M*
2025-09-30$118.70M(m)$16.28M$108.63M(m)(m)-$12.59M
2025-06-30$102.66M$6.24M$15.59M$103.01M(m)$0.00-$20.34M
2025-03-31$78.33M$5.21M$14.41M$85.00M(m)$0.00-$25.12M
2024-09-30$48.12M(m)$12.13M$57.91M(m)(m)-$23.42M
2024-06-30$40.81M(m)$12.32M$58.79M(m)(m)-$33.29M
2024-03-31$27.61M(m)$12.07M$51.58M(m)(m)-$35.73M
2023-09-30$1.87M(m)$12.11M(m)(m)$0.00-$39.15M
2023-06-30$0.00$0.00$12.55M(m)(m)$0.00-$31.42M
2023-03-31$2.50M$0.00$12.36M(m)(m)$0.00-$23.42M
2022-09-30$0.00$0.00$10.91M(m)(m)-$5.00K-$22.51M
2022-06-30$15.28M$522.00K$9.60M(m)$20.50M$0.00-$5.74M
2022-03-31$539.00K$33.00K$12.08M(m)$20.06M$1.00K-$20.24M
2021-09-30$1.24M$65.00K$10.21M(m)$16.95M-$341.00K-$15.70M
2021-06-30$22.02M(m)$7.20M(m)$14.73M$29.00K$6.34M
2021-03-31$33.43M(m)$16.26M(m)$22.72M$313.00K$10.38M
2020-09-30$0.00(m)$7.99M(m)$10.14M$1.00K-$10.14M
2020-06-30$0.00(m)$1.74M(m)$3.26M$0.00-$3.25M
2020-03-31$0.00(m)$1.51M(m)$2.12M$0.00-$1.96M
2019-09-30(m)(m)$399.00K(m)$633.00K$0.00-$681.00K
2019-06-30(m)(m)(m)(m)(m)(m)-$831.00K
2019-03-31(m)(m)(m)(m)(m)(m)-$1.75M

Revenue and expense 6 month

Period endRevenueCost of revenueResearch and developmentSelling, general and administrativeOperating expensesIncome taxNet income
2026-06-30$335.97M$21.51M$53.36M$287.13M(m)$5.07M-$25.52M
2025-06-30$181.00M$11.45M$30.00M$188.01M(m)$0.00-$45.46M
2024-06-30$68.43M(m)$24.39M$110.37M(m)(m)-$69.02M
2023-06-30$2.50M$0.00$24.90M(m)(m)$0.00-$54.84M
2022-06-30$15.82M$555.00K$21.68M(m)$40.56M$1.00K-$25.98M
2021-06-30$55.45M(m)$23.46M(m)$37.45M$342.00K$16.72M
2020-06-30$0.00(m)$3.25M(m)$5.38M$0.00-$5.21M

Revenue and expense 9 month

Period endRevenueCost of revenueResearch and developmentSelling, general and administrativeOperating expensesIncome taxNet income
2025-09-30$299.69M(m)$46.29M$296.64M(m)(m)-$58.05M
2024-09-30$116.55M(m)$36.51M$168.28M(m)(m)-$92.44M
2023-09-30$4.37M(m)$37.01M(m)(m)$0.00-$93.99M
2022-09-30$15.82M$555.00K$32.60M(m)(m)-$4.00K-$48.49M
2021-09-30$56.69M$2.10M$33.67M(m)$54.40M$1.00K$1.02M
2020-09-30$0.00(m)$11.24M(m)$15.52M$1.00K-$15.34M
2019-09-30(m)(m)$2.46M(m)$3.21M$1.00K-$3.26M

Revenue and expense 12 month

Period endRevenueResearch and developmentSelling, general and administrativeOperating expensesIncome taxNet income
2025-12-31$451.36M$64.32M$427.32M(m)$2.06M-$66.00M
2024-12-31$182.95M$53.39M$237.31M(m)$0.00-$116.00M
2023-12-31$17.45M$50.31M$108.70M$160.60M$0.00-$136.00M
2022-12-31$25.82M$42.62M$44.95M$88.53M-$4.00K-$62.09M
2021-12-31$57.03M$41.71M(m)$69.18M$55.00K-$13.83M
2020-12-31$0.00$18.83M(m)$27.00M$1.00K-$26.81M
2019-12-31(m)$3.16M(m)$4.30M$1.00K-$4.67M
2018-12-31(m)(m)(m)(m)(m)-$1.32M

Similar stocks

Stock NameCountryMarket CapPE Ratio
Denali Therapeutics Inc. (DNLI)United States$3.274B-8.04
Relay Therapeutics, Inc. (RLAY)United States$3.884B-14.30
Beam Therapeutics Inc. (BEAM)United States$2.549B-41.51
Greenland Mines Ltd (GRML)United States$2.362B
BIOCRYST PHARMACEUTICALS INC (BCRX)United States$2.175B-6.63
ADMA BIOLOGICS, INC. (ADMA)United States$2.131B11.16
Kodiak Sciences Inc. (KOD)United States$2.090B-10.12
RECURSION PHARMACEUTICALS, INC. (RXRX)United States$2.080B-3.78
Vericel Corp (VCEL)United States$2.011B93.97
Adaptive Biotechnologies Corp (ADPT)United States$4.719B-53.43